Making up for lost time 🙌

Down the rabbit hole once more 😎 

Topics covered: the new pancreatic cancer drug daraxonrasib and its rash side effect, survival benefit, and cost; what makes pancreatic cancer especially deadly; Vinay’s clinical background across hematology and oncology; how mechanistically cancer actually kills; the challenge of finding good podcast guests and why authenticity matters more than plugging a product; vaccine mandates and the difference between individual versus population-level benefit; the USPSTF’s recent upheaval and the challenge of evidence-based guidelines on contested topics like depression screening, mammograms, and prostate cancer screening; observational versus randomized evidence, with examples spanning flu vaccines, shingles vaccines and dementia, and Tylenol in pregnancy and autism; the OpenAI Navier-Stokes controversy and AI’s role in mathematics; AI in medicine and a JAMA perspective piece on AI replacing physicians; statins, coronary calcium scores, and personal decision-making around cardiovascular risk; weight stigma in medical training and the complexity of obesity; alternative medicine, longevity influencers, and Vinay’s evolving views on certainty; the ethics and mechanics of prediction markets and biotech stock betting; and reflections on active listening and communication style on the show.